PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

• Status: Recruiting
• Trial end date: 2022-02-02
• Target enrollment: 0
• Participant gender: Male

Summary

This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham

Criteria

Inclusion Criteria:

• Biopsy-proven treatment-naïve prostate adenocarcinoma with pelvic metastases known to suspected on standard-of-care staging imaging

• Eligibility and plan to undergo definitive radiation therapy for prostate cancer per established standard-of-care radiation oncology clinical guidelines

• Be at least 18 years of age

Exclusion Criteria:

• Inability to tolerate or undergo PET/MRI or PET/CT

• Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.)

• Recurrent prostate adenocarcinoma

• Known distant metastatic disease

• Current or prior treatment for prostate cancer

• Known allergy to glucagon

• Previous diagnosis of insulinoma or pheochromocytoma